Publication Rights 5 Práva Na Zveřejnění Sample Clauses

Publication Rights 5 Práva Na Zveřejnění. 5.1 Study Transparency and Publication 5.1Transparentnost a publikování Studie Before commencement of the Study, GSK will register the Study with a public clinical trials registry. GSK will make public a summary of the Protocol and a summary of the Study results from all Study sites in one or more publicly accessible worldwide registers at any time after the commencement of the Study. GSK will also post the full Study Protocol and statistical analysis plan at the time of results summary posting. Institution and Investigator agree that GSK may make public the names of the Investigator and Institution as part of a list of investigators and institutions conducting the Study when making either protocol or results summary register postings. Před zahájením Studie ji GSK zaregistruje ve veřejném registru klinických hodnocení. Kdykoli po zahájení Studie GSK zveřejní souhrn Protokolu a souhrn výsledků Studie ze všech míst provádění Studie v jednom nebo vícerých veřejně přístupných celosvětových registrech. V době zveřejnění souhrnu výsledků GSK také zveřejní úplný Protokol Studie a plán statistické analýzy. Poskytovatel a Zkoušející souhlasí s tím, že při zveřejnění protokolu nebo souhrnu výsledků v registru může GSK zveřejnit jména Zkoušejícího a Poskytovatele jako součást seznamu zkoušejících a zdravotnických zařízení provádějících Studii. Institution and Investigator shall have the right to publish or present the results of Institution’s and Investigator’s activities conducted under this Agreement, including Study Data, only in accordance with the requirements of this Section. Institution and Investigator agree to submit any proposed Poskytovatel a Zkoušející budou oprávněni publikovat a prezentovat výsledky činnosti Poskytovatele a Zkoušejícího, jež je prováděná na základě této Smlouvy, a to včetně Studijních dat a údajů, výlučně v souladu s požadavky stanovenými v tomto Článku. Poskytovatel a Zkoušející souhlasí, publication or presentation to GSK for review at least thirty (30) days prior to submitting any such proposed publication to a publisher or proceeding with such proposed presentation. Within thirty (30) days of its receipt, GSK shall advise Institution and/or Investigator, as the case may be, in writing of any information contained therein which is Confidential Information (other than Study Data) or which may impair the availability of patent protection for Inventions. GSK shall have the right to require Institution and/or Investigator, as applicable,...
Sample 1Sample 2See All (11)
AutoNDA by SimpleDocs
Publication Rights 5 Práva Na Zveřejnění. 5.1 Publication and Disclosure 5.1. Publikování a zpřístupnění Institution and Investigator shall have the right to publish or present the results of Institution’s activities conducted under this Agreement, including Study Data, only in accordance with the requirements of this Section. Institution and Investigator agree to submit any proposed publication or presentation to Sponsor for review at least sixty (60) days prior to submitting any such proposed publication to any other party. Within sixty (60) day period, Sponsor shall advise Institution and/or Investigator, as the case may be, in writing of any information contained therein which is Confidential Information (other than Study Data) or which may impair the availability of patent protection for Inventions. Sponsor shall have the right to require Institution and/or Investigator, as applicable, to remove specifically identified Confidential Information (other than Study Data) and/or to delay the proposed publication or presentation for an additional ninety (90) days to enable Sponsor to seek patent protection for Inventions. Zdravotnické zařízení a Zkoušející budou oprávněni publikovat a prezentovat výsledky činnosti Zdravotnického zařízení, jež je prováděná na základě této Smlouvy, a to včetně Studijních dat a údajů, výlučně v souladu s požadavky stanovenými v tomto Článku. Zdravotnické zařízení a Zkoušející souhlasí, že Zadavateli předloží jakoukoli navrhovanou publikaci a prezentaci pro účely jejich kontroly ve lhůtě alespoň šedesáti (60) dnů před předložením jakékoli takové publikace jakékoli jiné straně. Ve lhůtě šedesáti (60) dnů se Zadavatel písemně vyjádří Zdravotnickému zařízení a/nebo Zkoušejícímu, vždy dle podmínek konkrétního případu, ve vztahu k jakékoli informaci obsažené v takových materiálech, jež představuje Důvěrnou informaci (odlišnou od Studijních dat a údajů) nebo jež může představovat překážku možnosti dosažení patentové ochrany příslušného Objevu. Zadavatel bude oprávněn požadovat vůči Zdravotnickému zařízení a/nebo Zadavateli, vždy dle podmínek konkrétního případu, odstranění definovaných informací označených jako Důvěrné informace (jež jsou odlišné od Studijních dat a údajů) a/nebo požadovat odložení navrhované publikace či prezentace po dobu dodatečných devadesát (90) dnů, aby umožnil Zadavateli uplatnění patentové ochrany ve vztahu k takovému Objevu. 5.2 Multi-Center Publications 5.2 Multicentrické publikování Section 5.1, Institution and Investigator agree that they shall n...
Sample 1See All (6)
Publication Rights 5 Práva Na Zveřejnění. The Institution and the Investigator shall be entitled to publish the results of, or make presentations related to, the Study, provided that any publications or presentations to be made within 2 years of completion of the Study shall require the Sponsor’s prior written consent. All such publications or presentations shall (i) be consistent with academic standards and International Committee of Medical Journal Editors guidelines, (ii) not be false or misleading, (iii) comply with all Applicable Laws, (iv) not be made for any commercial purpose. Zdravotnické zařízení a Zkoušející mají právo publikovat výsledky Studie a pořádat prezentace související se Studií pod podmínkou, že veškeré publikace nebo prezentace před uplynutím 2 let od dokončení Studie podléhají předchozímu písemnému schválení Zadavatelem. Veškeré takové publikace a prezentace (i) musejí splňovat akademické standardy a zásady Mezinárodního výboru šéfredaktorů lékařských časopisů, (ii) nesmějí být nepravdivé nebo zavádějící, (iii) musejí být v souladu s Platnými právními předpisy a (iv) nesmějí sloužit komerčním účelům. 5.1. The Institution and/or the Investigator shall provide the Sponsor with copies of any materials relating to the Study, or the Developed Technologies that either intends to publish (or submit for publication) or make any presentations relating to, at least thirty (30) days in advance of publication, submission or presentation. 5.1. Zdravotnické zařízení nebo Zkoušející poskytnou Zadavateli kopie veškerých materiálů týkajících se Studie nebo Vyvinutých technologií, které budou chtít publikovat (nebo odevzdat k publikování) nebo o nichž budou chtít vést prezentaci, nejpozději třicet (30) dnů před publikací, odevzdáním k publikování nebo prezentací. 5.2. At the request of the Sponsor, the Institution and/or the Investigator. 5.
Sample 1Sample 2See All (5)
Publication Rights 5 Práva Na Zveřejnění. 5.1 Publication and Disclosure Institution shall have the right to publish or present the results of Institution’s activities conducted under this Agreement, including Study Data, only in accordance with the requirements of this Section 5. Institution agrees to submit any proposed publication or presentation to Sponsor for review at least thirty (30) days prior to submitting any such proposed publication to a publisher or proceeding with such proposed presentation. Within thirty (30) days of its receipt, Sponsor shall advise Institution in writing of any information contained therein which is Confidential Information (other than Study Data) or which may impair the availability of patent protection for Inventions. Sponsor shall have the right to require Institution, to remove specifically identified Confidential Information (other than Study Data) and/or to delay the proposed publication or presentation for an additional sixty (60) days to enable Sponsor to seek patent protection for Inventions.
Sample 1
Publication Rights 5 Práva Na Zveřejnění. 5.1 The Institution and the Principal Investigator shall be entitled to publish the results of, or make presentations related to, the Study, as indicated in this Section 05. If this Study is part of a multi-center clinical trial, Institution and Investigator agree not to independently publish the results of the Study until first occurrence of one of the following: (i) multi-center primary Publication is published; (ii) no multi-center primary publication is submitted within two (02) years after conclusion, abandonment, or termination of the Study at all sites; or (iii) Sponsor confirms in writing there will be no multi-center primary Publication . All such publications or presentations shall (i) be consistent with academic standards and International Committee of Medical Journal Editors (ICMJE) guidelines, (ii) not be false or misleading, (iii) comply with all Applicable Laws, (iv) not be made for any commercial purpose. 5.1 Zdravotnické zařízení a Hlavní zkoušející budou oprávněni publikovat výsledky Studie nebo zveřejňovat prezentace související se Studií tak, jak je uvedeno v tomto článku 5. Je-li Studie součástí multicentrického klinického hodnocení, Zdravotnické zařízení a Zkoušející se zavazují, že nezveřejní nezávisle výsledky Studie dříve, než poprvé dojde k jedné z níže uvedených situací: (i) bude publikována multicentrická primární publikace; (ii) do dvou (2) let od uzavření, opuštění nebo ukončení Studie ve všech místech provádění klinického hodnocení nebude předložena žádná multicentrická primární publikace; nebo (iii) Zadavatel písemně potvrdí, že nebude vydána žádná multicentrická primární publikace. Všechny tyto publikace nebo prezentace (i) budou v souladu s akademickými standardy a směrnicemi Mezinárodního výboru redaktorů lékařských časopisů (ICMJE – International Committee of Medical Journal Editors), (ii) nebudou falešné nebo zavádějící, (iii) budou v souladu se všemi Příslušnými právními předpisy, (iv) nebudou vydány za jakýmkoli komerčním účelem. 5.2 The Institution and/or the Investigator shall provide the Sponsor with copies of any materials relating to the Study, or the Developed Technologies that either intends to publish (or submit for publication) or make any presentations relating to, at least thirty (30) days in advance of publication, submission or presentation. 5.2 Zdravotnické zařízení nebo Zkoušející poskytnou Zadavateli kopie veškerých materiálů týkajících se Studie nebo Vyvinutých technologií, které budou chtít publikova...
Sample 1
Publication Rights 5 Práva Na Zveřejnění. 1Publication and Disclosure 5.1. Publikování a zpřístupnění
Sample 1
Publication Rights 5 Práva Na Zveřejnění. 5.1 Publication and Disclosure Institution and Investigator shall have the right to publish or present the results of Institution’s and Investigator’s activities conducted under this Agreement, including that Study Data, which was obtained at Institution, only in accordance with the requirements of this Section. Institution and Investigator agree to submit any proposed publication or presentation to Sponsor for review at least sixty (60) days prior to submitting any such proposed publication to a publisher or proceeding with such proposed presentation. Within forty-five (45) days of its receipt, Sponsor shall advise Institution and/or Investigator, as the case may be, in writing of any information contained therein which is Confidential Information or which may impair the availability of patent protection for Inventions. Institution and/or Investigator, as applicable, shall comply with any request by Sponsor to remove specifically identified Confidential Information (other than Study Data generated at Institution in the conduct of the Study that is necessary for the scientific integrity of such publication or presentation) and/or to delay the proposed publication or presentation for an additional sixty (60) days to enable Sponsor to seek patent protection for Inventions.
Sample 1
AutoNDA by SimpleDocs
Publication Rights 5 Práva Na Zveřejnění 
Sample 1Sample 2Sample 3See All (25)

Related to Publication Rights 5 Práva Na Zveřejnění

  • Publication Rights Where activities supported by this Agreement produce books, films, or other such copyrighted materials issued by the PROVIDER, the PROVIDER may copyright, but shall acknowledge that MSHN reserves a royalty-free, non-exclusive and irrevocable license to reproduce, publish and use such materials and to authorize others to reproduce and use such materials. This cannot include service consumer information or personal identification data. Any copyrighted materials or modifications bearing acknowledgment of or by MSHN must be approved by MSHN prior to reproduction and use of such materials. The PROVIDER shall give recognition to the MSHN in any and all publication papers and presentations arising from the program and service contract herein; MSHN will do likewise. In all cases, whether the material is copyrighted or not, the PROVIDER shall acknowledge on all of its publications, reports, brochures, flyers, etc., that public funds, provided by the State of Michigan through MSHN, were used to support the cost of publication and the delivery of the service, program, event, or publication described by it.

  • Transfer of Incentive Distribution Rights The General Partner or any other holder of Incentive Distribution Rights may transfer any or all of its Incentive Distribution Rights without the approval of any Limited Partner or any other Person.

  • Information Rights So long as the Holder holds this Warrant and/or any of the Shares, the Company shall deliver to the Holder (a) promptly after mailing, copies of all communiques to the shareholders of the Company, (b) within ninety (90) days after the end of each fiscal year of the Company, the annual audited financial statements of the Company certified by independent public accountants of recognized standing and (c) within forty-five (45) days after the end of each of the first three quarters of each fiscal year, the Company's quarterly, unaudited financial statements.

  • Synchronization Rights The Licensor hereby grants limited synchronization rights for One (1) music video streamed online (Youtube, Vimeo, etc..) for up to 500000 non-monetized video streams on all total sites. A separate synchronization license will need to be purchased for distribution of video to Television, Film or Video game.

  • FEDERATION RIGHTS Section 1. Upon written request, the Employer shall make available one copy of all public information relevant to negotiations or necessary for the proper enforcement of this Agreement, providing such information is readily available and accessible. The Employer may charge reasonable and customary fees for substantial amounts of services. Section 2. The internal business of the Federation shall normally be conducted by employees during their non-duty hours. However, selected and designated Federation officers or appointees shall be allowed a reasonable amount of paid time to investigate and process grievance and arbitration matters. Section 3. The Federation's staff will be allowed to visit work areas during working hours provided that advance permission is received and that the visit shall not unduly disrupt work in progress. Section 4. Whenever members of the bargaining unit are scheduled by the Employer to participate during working hours in conferences or meetings, they shall be granted the necessary release time. Section 5. The Employer shall ensure reasonable access to the Federation an up-to-date policy manual of its rules, regulations, and policies on employment related matters. The Federation shall be notified of any proposed changes or additions to personnel rules, regulations and policies issued by the Department of Administration and the Department of Public Health & Human Services sufficiently in advance to allow discussion and comment by the Federation. Section 6. The Employer, within 30 days of the signing of this Agreement, shall present the Federation with a list of the names and addresses of all current employees covered by this Agreement, and shall update such list each month for all new hires. Section 7. Federation representatives shall have the right to inspect an employee's personnel file with a specific authorization in writing by the employee. Federation representatives may obtain a copy of a document related to a formal grievance provided specific authorization is obtained in writing from the employee. Section 8. The Federation shall have the right to adequate space on bulletin boards for posting notices and shall have access, subject to availability, to a meeting room on the Employer's premises. Section 9. The Employer agrees to provide notice to the Federation of any suspension or discharge of any member of the bargaining unit. Section 10. The Employer agrees to provide 20 working days advance notice to the Federation of any employee layoff, along with an opportunity to comment on the layoff. Section 11. The Employer shall allow a maximum of 18 employees release time for Federation members to attend the MFPE Annual Conference with prior management approval for time off. Section 12. The Federation shall be granted the opportunity to provide membership information to union represented positions during new employee orientation or the onboarding process.

  • Anti-Dilution Rights (a) If at any time after the date hereof the Company declares or authorizes any dividend (other than a cash dividend), stock split, reverse stock split, combination, exchange of Shares, or there occurs any recapitalization, reclassification (including any consolidation or merger), sale or acquisition of property or stock, reorganization or liquidation, or if the outstanding Shares are changed into the same or a different number of Shares of the same or another class or classes of stock of the Company, then the Company shall cause effective provision to be made so that the Holder shall, upon exercise of this Warrant following such event, be entitled to receive the number of shares of stock or other securities or the cash or property of the Company (or of the successor corporation or other entity resulting from any consolidation or merger) to which the Warrant Shares (and any other securities) deliverable upon the exercise of this Warrant would have been entitled if this Warrant had been exercised immediately prior to the earlier of (i) such event and (ii) the record date, if any, set for determining the stockholders entitled to participate in such event, and the Exercise Price shall be adjusted appropriately so that the aggregate amount payable by the Holder upon the full exercise of this Warrant remains the same. The Company shall not effect any recapitalization, reclassification (including any consolidation or merger) unless, upon the consummation thereof, the successor corporation or entity shall assume by written instrument the obligation to deliver to the Holder the shares of stock, securities, cash or property that the Holder shall be entitled to acquire in accordance with the foregoing provisions, which instrument shall contain provisions calculated to ensure for the Holder, to the greatest extent practicable, the benefits provided for in this Warrant. (b) If, pursuant to the provisions of this paragraph 7, the Holder would be entitled to receive shares of stock or other securities upon the exercise of this Warrant in addition to the Shares issuable upon exercise of this Warrant, then the Company shall at all times reserve and keep available sufficient shares of other securities to permit the Company to issue such additional shares or other securities upon the exercise of this Warrant. (c) The Company shall at any time if so requested by the Holder furnish a written summary of all adjustments made pursuant to this paragraph 7 promptly following any such request.

  • Public Posting of Approved Users’ Research Use Statement The PI agrees that information about themselves and the approved research use will be posted publicly on the dbGaP website. The information includes the PI’s name and Requester, project name, Research Use Statement, and a Non-Technical Summary of the Research Use Statement. In addition, and if applicable, this information may include the Cloud Computing Use Statement and name of the CSP or PCS. Citations of publications resulting from the use of controlled-access datasets obtained through this DAR may also be posted on the dbGaP website.

  • Grant of Company Reacquisition Right Except to the extent otherwise provided by the Superseding Agreement, if any, in the event that the Participant’s Service terminates for any reason or no reason, with or without cause, the Participant shall forfeit and the Company shall automatically reacquire all Units which are not, as of the time of such termination, Vested Units (“Unvested Units”), and the Participant shall not be entitled to any payment therefor (the “Company Reacquisition Right”).

  • Registration Rights; Private Sales (a) If the Administrative Agent shall determine to exercise its right to sell any or all of the Collateral pursuant to PARAGRAPH 9 hereof, and if in the opinion of the Administrative Agent it is necessary or advisable to have such Collateral, or that portion thereof to be sold, registered under the provisions of the Security Act of 1933, as amended (the "Securities Act"), the Pledgor will use its best efforts to cause the applicable Issuer or Partnership to (i) execute and deliver, and use its best efforts to cause the directors, officers and representatives of the applicable Issuer or Partnership to execute and deliver, all such instruments and documents, and do or cause to be done all such other acts as may be, in the opinion of the Administrative Agent, necessary or advisable to register such Collateral, or that portion thereof to be sold, under the provisions of the Securities Act, (ii) to use its best efforts to cause the registration statement relating thereto to become effective and to remain effective for a period of one year from the date of the first public offering of such Collateral or that portion thereof to be sold, and (iii) to make all amendments thereto and/or to the related prospectus which, in the opinion of the Administrative Agent, are necessary or advisable, all in conformity with the requirements of the Securities Act and the rules and regulations of the Securities and Exchange Commission applicable thereto. The Pledgor agrees to use its best efforts to cause the applicable Issuer or Partnership to comply with the provisions of the securities or "Blue Sky" laws of any and all jurisdictions which the Administrative Agent shall designate and to make available to its security holders, as soon as practicable, an earnings statement (which need not be audited) which will satisfy the provisions of Section 11(a) of the Securities Act. For the purposes of this SECTION 10.(A), "applicable Issuer or Partnership" shall mean each Issuer or Partnership which is a direct or indirect wholly-owned Subsidiary of the Pledgor. (b) The Pledgor recognizes that the Administrative Agent may be unable to effect a public sale of any or all the Collateral, by reason of certain prohibitions contained in the Securities Act and applicable state securities laws or otherwise, and may be compelled to resort to one or more private sales thereof to a restricted group of purchasers which will be obliged to agree, among other things, to acquire such securities for their own account for investment and not with a view to the distribution or resale thereof. The Pledgor acknowledges and agrees that any such private sale may result in prices and other terms less favorable than if such sale were a public sale and, notwithstanding such circumstances, agrees that any such private sale shall be deemed to have been made in a commercially reasonable manner. The Administrative Agent shall be under no obligation to delay a sale of any of the Collateral for the period of time necessary to permit the applicable Issuer or Partnership to register such securities for public sale under the Securities Act, or under applicable state securities laws, even if the applicable Issuer or Partnership would agree to do so. (c) The Pledgor further agrees to use its best efforts to do or cause to be done all such other acts as may be necessary to make such sale or sales of all or any portion of the Collateral pursuant to this PARAGRAPH 10 valid and binding and in compliance with any and all other applicable Laws and applicable requirements of the Insurance Regulators. The Pledgor further agrees that a breach of any of the covenants contained in this PARAGRAPH 10 will cause irreparable injury to the Administrative Agent and the Lenders not compensable in damages, that the Administrative Agent and the Lenders have no adequate remedy at law in respect of such breach and, as a consequence, that each and every covenant contained in this PARAGRAPH 10 shall be specifically enforceable against the Pledgor, and the Pledgor hereby waives and agrees not to assert any defenses against an action for specific performance of such covenants except for a defense that no Event of Default has occurred under the Credit Agreement.

  • No Registration Rights to Third Parties Without the prior written consent of the Holders of a majority in interest of the Registrable Securities then outstanding, the Company covenants and agrees that it shall not grant, or cause or permit to be created, for the benefit of any person or entity any registration rights of any kind (whether similar to the demand, “piggyback” or Form F-3 registration rights described in this Section 2, or otherwise) relating to any securities of the Company which are senior to, or on a parity with, those granted to the Holders of Registrable Securities.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!